A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Inclusion Criteria:

• At the time of obtaining informed consent, participants age should be greater thanor equal to (>=)18 years and less than or equal to (<=) 55 years.

• Participants who are overtly healthy as determined by medical evaluation includingmedical history, physical examination, laboratory tests, and cardiac monitoring.

• Body weight >=40 kilogram (kg) and body mass index (BMI) within the range >=18 to <=32 kilogram per meter square (kg/m^2).

• Participants who are negative on a single test for severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) (approved molecular polymerase chain reaction [PCR]laboratory or point of care test), performed on the day of admission. A negativeresult is required prior to the administration of study intervention on Day 1.

• Contraceptive use by men and women should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies.

• Capable of giving written informed consent.

Exclusion Criteria:

• Current presence or history of cardiovascular, respiratory, hepatic, renal,gastrointestinal, endocrine, hematological, or neurological disorders.

• Current or chronic history of liver disease or known hepatic or biliaryabnormalities.

• History of ongoing or clinically relevant seizure disorder within the previous 2years, including participants who have required treatment for seizures within thistime period.

• Positive SARS-CoV-2 polymerase chain reaction test, having signs and symptoms whichin the opinion of the investigator are suggestive of coronavirus disease 2019 (COVID-19) (i.e., fever, cough etc) within 14 days of inpatient admission, or havingcontact with known COVID-19 positive person/s in the 14 days prior to inpatientadmission.

• Human immunodeficiency virus (HIV-1 or HIV-2) infection as indicated by positiveantibody/antigen test.

• History of or on-going high-risk behaviors that, in the opinion of the investigator,may put the participant at increased risk for HIV infection including, but notlimited to, participants in HIV discordant relationships, or men who report currentor prior unprotected anal sex with other men and those reporting prior or currentinjecting drug use.

• Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibodytest result at screening or within 3 months prior to first dose of study treatment.

• Abnormal blood pressure.

• Evidence of previous myocardial infarction.

• Any conduction abnormality (including but not specific to left or right completebundle branch block, atrioventricular [AV] block [2nd degree or higher], Wolff-Parkinson-White [WPW] syndrome).

• Any significant arrhythmia which, in the opinion of the investigator or the medicalmonitor, will interfere with the safety for the individual participant.

• One or more exclusionary values for a screening Electrocardiogram (ECG).

• Alanine transaminase (ALT) >1.5x upper limit of normal (ULN).

• Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin isfractionated and direct bilirubin <35 percent [%]).

• Estimated Glomerular Filtration Rate (eGFR) <60 milliliter per minute (mL/min) usingthe Chronic Kidney Disease

• Improved Prediction Equations (CKD-EPI) Creatinine Equation (2021).

• Hemoglobin <12.5 gram per deciliter (g/dL) for men and <11 g/dL for women.

• Positive pre-study drug/alcohol screen.

• Regular use of tobacco- or nicotine-containing products within 3 months prior toscreening; or urinary cotinine levels indicative of smoking or history or regularuse of tobacco- or nicotine-containing products (e.g., nicotine patches orvaporizing devices).

• Regular alcohol consumption within 6 months prior to the study defined as an averageweekly intake of >14 units for males or >7 units for females.

• Regular use of known drugs of abuse.

• Concurrent participation in another clinical trial (except imaging trials); or hasparticipated in a clinical trial and received an investigational product within thefollowing time period prior to the first dosing day in this study: 30 days, 5half-lives or twice the duration of the biological effect of the investigationalproduct (whichever is longer).

• Participation in the study would result in loss of blood or blood products in excessof 500 mL within 56 days.

• Exposure to more than four (4) new chemical entities within 12 months prior to thefirst dosing day.

• History of sensitivity to any of the study interventions (or components thereof), ahistory of drug allergy or other allergy that, in the opinion of the investigator ormedical monitor, contraindicates their participation, including a knownhypersensitivity to hyaluronidases.

• Current or anticipated need for chronic anti-coagulation therapy.

• Hereditary coagulation and platelet disorders (e.g., hemophilia or Von Willebranddisease [VWD]).

• Participant has a tattoo overlying the location of injection or an underlying skindisease or condition (e.g., infection, inflammation, dermatitis, eczema, drug rash,drug allergy, psoriasis, food allergy, urticaria) that, in the opinion of theinvestigator, may interfere with interpretation of injection site reactions oradministration of study intervention.

• Any other clinical condition, behavior or prior therapy that, in the opinion of theinvestigator, would make the participant unsuitable for the study; unable to complywith dosing requirements; or unable to comply with study visits.

• Participant who in the investigator's judgment poses a significant suicidality risk.Participant's history of suicidal behavior and/or suicidal ideation should beconsidered when evaluating for suicide risk.